Xcovery Holdings, Inc., an oncology focused bio-pharmaceutical company, has acquired a majority, controlling stake in Meryx Inc.
Meryx is a clinical stage immuno-oncology firm that develops TKIs for a range of hematologic and solid malignancies. The combined firm will serve to accelerate and enhance both firm’s mission to develop small molecule oncology drugs.
“Meryx has done a remarkable job of developing an innovative cutting-edge oncology pipeline. We are looking forward to building on this impressive track record and collaborating closely with its team to advance the clinical trials of these promising drug candidates,” said Lieming Ding, M.D., chairman of Xcovery board.